ReviewFrontiers in pharmacology2025
Compliant immune response of silk-based biomaterials broadens application in wound treatment.
Review in Frontiers in pharmacology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Application of Transgenic Silk Fibroin to Biomaterials.Biotechnology and bioengineering · 2026Review
- Silk-Fibroin-Based Adhesive Hydrogels: Mechanistic Insights and Biomedical ApplicationsA Review.ACS omega · 2026Review
- Structural and immunogenic evaluation of silk proteins from Bombyx mori using advanced bioinformatics and deep learning for biomaterials applications.Journal, genetic engineering & biotechnology · 2026Article
- Nanoadjuvant-integrated organic biomaterials for immune engineering: Mechanisms, design strategies, and translational applications.Materials today. Bio · 2026Review
- Ultra-thin elastin-based membranes as an innovative dressing to enhance skin wound healing.Materials today. Bio · 2026Article
- Silk protein plastics for sustained and controlled drug release.International journal of pharmaceutics · 2026Article
- Silk sericin and its biomedical applications: extraction methods, genetic insights (Ser1-Ser6), and developments of multifunctional biomaterials for tissue regeneration.Frontiers in bioengineering and biotechnology · 2026Review
- Silk Fibroin-Derived Smart Living Hydrogels for Regenerative Medicine and Organoid Engineering: Bioactive, Adaptive, and Clinically Translatable Platforms.Gels (Basel, Switzerland) · 2025Review
- Recycled Sericin Biopolymer in Biotechnology and Bioelectronics.Bioengineering (Basel, Switzerland) · 2025Review
- Review
- Reduction-Responsive Nanoparticles Self-Assembled from Sericin-ss-Doxorubicin Conjugate for Hydrophobic IR780 Delivery with Integration of Antitumor Chemo-Phototherapy.International journal of nanomedicine · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The unique properties of sericin and silk fibroin (SF) favor their widespread application in biopharmaceuticals, particularly in wound treatment and bone repair. The immune response directly influences wound healing cycle, and the extensive immunomodulatory functions of silk-based nanoparticles and hydrogels have attracted wide attention. However, different silk-processing methods may trigger intense immune system resistance after implantation into the body. In this review, we elaborate on the inflammation and immune responses caused by the implantation of sericin and SF and also explore their anti-inflammatory properties and immune regulatory functions. More importantly, we describe the latest research progress in enhancing the immunotherapeutic and anti-inflammatory effects of composite materials prepared from silk from a mechanistic perspective. This review will provide a useful reference for using the correct processes to exploit silk-based biomaterials in different wound treatments.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.